Skip to main content
Equibles
NVAX logo

NVAX · Novavax Inc · Metrics

Track NVAX — free

Use NVAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.76 -1.22 (-12.22%) At close · Nov 12 Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
165.01M
Volume · Nov 12 7.01M Avg daily vol (3M) 6.74M

NVAX metrics

86 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.76
Market cap
$1.45B

Price action

23 metrics
Price change (1W)
-6.3%
Price change (30D)
-22.2%
Price change (3M)
+25.4%
Price change (6M)
+8.1%
Price change (YTD)
+48.5%
Price change (1Y)
+34.1%
Trailing year
Price change (5Y)
-94.1%
52-week high
$12.82
52-week low
$6.22
Change from 52-week high
-22.2%
Change from 52-week low
+60.5%
Annualized volatility
72.6%
Annualized volatility (3M)
87.4%
Implied volatility (30D)
59.6%
IV rank (1Y)
6.6
IV percentile (1Y)
8.6
Beta
2.1
RSI (14D)
46.2
Price vs SMA 50
-5.9%
Price vs SMA 200
+6.8%
Avg volume (3M)
6.68M
Relative volume
0.9
Average dollar volume
$70.54M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
165.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.2×
reciprocal yield 31.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
4.0×
reciprocal yield 25.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 89.6%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 63.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
78.0%
Operating margin
-21.2%
Trailing 12 months
Net margin
-18.6%
Gross profit (TTM)
$321.12M
Operating profit (TTM)
−$87.39M
Net income (TTM)
−$76.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.29
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.45
Gross profit per diluted share (TTM)
$1.91
Operating profit per diluted share (TTM)
$-0.54
EBITDA per diluted share (TTM)
$-0.45
Net income per diluted share (TTM)
$-0.47
Operating cash flow per diluted share (TTM)
$-1.44
Free cash flow per diluted share (TTM)
$-10.61
Capital expenditures per diluted share (TTM)
$0.90
R&D per diluted share (TTM)
$1.76
Stock compensation per diluted share (TTM)
$0.19
Book value per share
$-0.79

Growth

11 metrics
Revenue growth YoY
-3.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$411.65M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.6%
Year over year · more shares
Revenue CAGR (3Y)
-17.2%
Revenue CAGR (5Y)
+18.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-8.6%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$72.71M
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
-4.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$330.27M
Latest balance sheet
Cash & equivalents
$222.46M
Total assets
$888.00M
Total debt
$292.09M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$238.95M
Capital expenditures (TTM)
$82.40M
R&D (TTM)
$294.49M
SG&A (TTM)
$113.21M
Stock compensation (TTM)
$31.73M
R&D / revenue
71.5%
Stock compensation / revenue
7.7%

Ownership (13F)

9 metrics
13F filers
268
13F filer change QoQ
+9
Institutional ownership
77.6%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
17.1%
Private-fund adviser ownership
12.0%
Active holders' share change QoQ
-6.6%
Holder tenure
12.9
Price vs estimated holder cost
+0.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.7%

Short interest

3 metrics
Short interest
28.1%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1000694 CUSIP 670002401 13F (30d) 181 filings 154 filers Visit website Investor relations